Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alimemazine is a first-generation phenothiazine derivative antihistamine primarily used to relieve allergic skin conditions such as pruritus and urticaria. It is also employed as a sedative for young children before surgical procedures and has antiemetic properties for the prevention of motion sickness. Alimemazine acts mainly by antagonizing the histamine H1 receptor, thereby blocking the effects of endogenous histamine in allergic reactions. Its central nervous system penetration leads to sedative and hypnotic effects. Additionally, it exhibits weak anticholinergic activity and some anti-serotonin effects. Although structurally related to antipsychotic phenothiazines like chlorpromazine, alimemazine is not used clinically as an antipsychotic[1][2][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alimemazine.